TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound and Photoacoustic Imaging for Cervical Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
* Diagnosis of cervical cancer of any stage that will be treated with radiation therapy and concurrent chemotherapy.~* At least 18 years of age.~* Not pregnant and/or breastfeeding.~* Able to understand and willing to sign an IRB-approved written informed consent document.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transvaginal probe (Photoacoustic + ultrasound imaging) (Type: EXPERIMENTAL): * A transvaginal imaging probe using ultrasound and photoacoustic imaging will be inserted into the vagina and will use different frequencies of lights to create images~* This will occur before the first standard of care treatment, mid-treatment, end of treatment, and approximately 3 months after the end of treatment for a total of 4 imaging time points

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: BKM120+Abiraterone Acetate for Metastatic CRPC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed CRPC with metastatic bone disease~* Castrate resistant disease~* Life expectancy of at least 6 months~* At least four weeks from previous treatment~* At least four weeks since any major surgery or radiation therapy~* Using highly effective contraception~Exclusion Criteria:~* Thromboembolism within past 6 months~* History of diabetes~* Prior therapy with abiraterone~* Prior therapy with PI3K inhibitor~* Alcohol or drug dependence currently or within past 6 months~* Contraindications to biopsy, such as bleeding disorders~* On anticoagulants such as warfarin or heparin~* Active malignancy other than skin cancer or superficial bladder cancer~* Untreated brain metastases~* Acute or chronic liver, renal disease or pancreatitis~* Mood disorders judged by the investigator to interfere with study participation~* Active cardiac disease or history of cardiac dysfunction~* Uncontrolled hypertension~* Known HIV, Hepatitis B or C~* Serious non-healing wound, ulcer or bone fracture~* Known or suspected allergy to BKM120, abiraterone or prednisone~* Impairment of GI function

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): BKM120+Abiraterone+Prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically or cytologically confirmed solid tumor malignancy AND hypertension, defined as a systolic pressure \> 130 OR a diastolic pressure \> 80~* Patients cannot be on active chemotherapy or radiation therapy; start of treatment with ACE-I or ARB must occur at least four weeks after the last dose of chemotherapy or radiation therapy~* Creatinine \< 2.5~* Potassium \< ULN~* Ability to understand and the willingness to sign a written informed consent document~* HIV positive patients are eligible to participate in this study~Exclusion Criteria:~* Patients who are pregnant or nursing due to significant risk to the fetus/infant~* Patients who are unable to take oral medications~* Patients who are currently taking an ACE-Inhibitor or ARB

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral benazepril hydrochloride once daily on days 1-7.
- Arm II (Type: EXPERIMENTAL): Patients receive oral lisinopril once daily on days 1-7.
- Arm III (Type: EXPERIMENTAL): Patients receive oral ramipril twice daily on days 1-7.
- Arm IV (Type: EXPERIMENTAL): Patients receive oral losartan potassium once daily on days 1-7.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Characterization of Sympathetic Nerve Activity in Stress Cardiomyopathy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of stress cardiomyopathy in the past~Exclusion Criteria:~* Coronary artery disease (CAD), primary coronary intervention (PCI) or coronary artery bypass graft (CABG)~* Cardiac dysfunction~* Heart failure~* Significant arrhythmias~* Severe chronic obstructive pulmonary disease (COPD)~* Diabetic neuropathy~* Pregnancy

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Study group (Type: EXPERIMENTAL): Subjects with documented stress cardiomyopathy who would serve as the study group. Sympathetic Nerve Activity; Mental StrCold Pressor Testess Test (Color Word Test); The Modified Oxford Technique for Baroreflex Sensitivity; Cold Pressor Test; Echocardiographic evaluation
- Control (Type: ACTIVE_COMPARATOR): Control subjects will be age and sex matched otherwise healthy people with no prior cardiac disease or other severe medical conditions. Sympathetic Nerve Activity; Mental Stress Test (Color Word Test); The Modified Oxford Technique for Baroreflex Sensitivity; Cold Pressor Test; Echocardiographic evaluation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with an established diagnosis of Crohn's disease who went into remission using corticosteroids within 4 weeks before the study~Exclusion Criteria:~* Any other treatment for the maintenance of remission of Crohn's disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Two Adjuvant Formulations of an Egg-Derived Pandemic Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* being healthy and ≥ 18 and ≤ 49 years of age~* willing and able to give informed consent~Exclusion Criteria:~* having participated in an influenza H5 vaccine trial in the past~* known to be allergic to any constituent of the vaccine~* serious adverse reactions to previous (influenza) vaccination~* currently participating in another clinical trial or having participated in any clinical trial in the month preceding the start of the study~* using medication that influences the immune system

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: EXPERIMENTAL): None
- 5 (Type: EXPERIMENTAL): None
- 6 (Type: EXPERIMENTAL): None
- 7 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Renal Denervation for Resistant Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* systolic BP ≥140mmHg or ≥130mmHg for patients with diabetes~* concurrent treatment with ≥3 anti-hypertensive drugs~Exclusion Criteria:~* renal artery anatomy ineligible for treatment~* eGFR \<15mL/min/1.73m2 (using Modification of Diet in Renal Disease (MDRD) calculation)~* female participants of childbearing potential must have negative pregnancy test prior to treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Renal Denervation Group (Type: EXPERIMENTAL): participants randomised to undergo the renal denervation procedure
- Usual care (Type: NO_INTERVENTION): participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Behavioral Activation and Antidepressant Medication in the Treatment of Adolescents With Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adolescents ages 13-17~* Current diagnosis of Major Depressive Disorder as determined by the Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS-PL), Children's Depression Rating Scale (CDRS-R) raw score \> 45 (T-score \> 65) at baseline~* Estimated full scale IQ \> 80 as determined by the Wechsler Intelligence Scale for Children (WISC)~* Able to receive outpatient care~* Willing to discontinue other psychosocial treatments~* Not taking psychotropic medications in the one month prior to consent, with the exception of psychostimulant medication prescribed for the treatment of attention-deficit/hyperactivity disorder (ADHD)~Exclusion Criteria:~* Current or past diagnosis of bipolar, schizophrenia, schizophreniform, schizoaffective disorders, or psychosis not otherwise specified~* Current diagnosis of developmental disorder, severe conduct disorder, life-threatening anorexia, obsessive-compulsive disorder, or autism-spectrum disorders~* Taking psychotropic medications prior to entry~* Estimated IQ \< 80~* Alcohol/drug dependence or abuse within the last 3 months~* Potential/confirmed neurological disorder or epilepsy~* Claustrophobia~* Presence of a medical condition that precludes fMRI~* Endorsement of imminent and serious suicidality~* Medical conditions for which treatment with fluoxetine is contraindicated or that take precedence over the presence of major depressive disorder (MDD)~* Pregnancy

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Behavioral Activation (Type: EXPERIMENTAL): None
- Fluoxetine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~Must meet all of the following criteria at the start of the Induction Period:~* Male or female aged ≥18 years and \<75 years at the time of providing informed consent.~* A diagnosis of CD with ileal involvement for at least 3 months prior to Screening.~* A CDAI score \>180 and \<350.~* Part B only: Active mucosal inflammation.~Key Exclusion Criteria:~* Stricture with obstructive syndrome \<3 months prior to Screening.~* Stenosis making endoscopic access to the terminal ileum difficult.~* Received treatment with high dose corticosteroid (≥40 mg prednisone daily) for \>5 weeks within 3 months prior to Screening.~* Part B only: Received \>3 prior biologic treatments or JAK inhibitors for CD including infliximab, ustekinumab, vedolizumab, adalimumab, certolizumab, risankizumab, and upadacitinib.~* Major surgery or significant trauma ≤4 weeks prior to Screening.~* Small bowel resection \>1 m in total or clinical manifestations of short bowel syndrome.~* Current stoma (ileostomy or a colostomy) or had a stoma in the last 6 months or any other intraabdominal surgery within 3 months prior to Screening.~* Started or stopped immunosuppressive therapy (thiopurine, methotrexate, tacrolimus, or other classical immunosuppressant) within 3 months prior to Screening.~* Received faecal microbial transplant within 3 months prior to Screening.~* Systemic infection or other serious infection requiring systemic treatment within 30 days prior to Screening.~* Pregnant, breastfeeding, or expecting to conceive during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Part A (Open-Label EXL01 Maintenance Therapy) (Type: EXPERIMENTAL): Oral EXL01 once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
- Part B (EXL01 Maintenance Therapy) (Type: EXPERIMENTAL): Oral EXL01 once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
- Part B (Placebo Maintenance Therapy) (Type: PLACEBO_COMPARATOR): Oral EXL01 matched placebo once daily for up to 24 weeks (after SoC corticosteroid induction therapy).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: LEGION™ Primary Safety and Efficacy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria: Subjects must meet all of the inclusion criteria:~* Subject is a candidate for the LEGION™ Primary Knee System according to the instructions for use~* Subject is of legal age and skeletally mature~* Subject is willing to sign and date an ethics-approved consent form and participate in the study~* Subject is willing to be available for ten-year follow-up postoperatively.~Exclusion Criteria: Subjects must not meet any of the exclusion criteria:~* Subject with immunosuppressive disorders~* Subject has grossly insufficient femoral or tibial bone stock~* Subject has an active localized or systemic infection~* Subject is pregnant~* Subject psychological or neurological conditions that would impair the subject's ability or willingness to restrict activities or follow medical advice during the course of this study~* Subject is a prisoner.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LEGION™ Primary (Type: OTHER): LEGION™ Primary Total Knee Arthroplasty (TKA)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* 1) IPF diagnosis for \<= 5 years prior to Visit 1 (screening). Confirmation of diagnosis of IPF in accordance is required for subject inclusion 2) Confirmed diagnosis of IPF by clinical characteristics, HRCT and surgical lung biopsy (if required) 3)Mild to moderate IPF to include all of the following at screening:~  1. FVC \>= 50% predicted normal~ 2. Partial pressure of oxygen in arterial blood (PaO2) of \>= 55 mmHg on room air or 50 mmHg at high altitude (\> 1500 meters), or oxygen saturation by pulse oximetry (SpO2) of \>= 90%on room air at rest~ 3. Hemoglobin-corrected diffusion capacity for carbon monoxide (DLCO) \>= 30% predicted normal 4) Be able to walk \>= 100 meters unassisted~Key Exclusion Criteria:~1. A FEV1/FVC ratio less than 0.70 at the time of screening (postbronchodilator)~2. The extent of emphysema on the HRCT is greater than the extent of fibrosis.~3. Currently listed for lung transplantation~4. Use of the following medications:~   1. Immunosuppressive medications (eg, methotrexate, cyclosporine, azathioprine, intramuscular long-acting depot corticosteroid) within 3 months prior to Visit 1 (screening). Oral prednisone \<= 15 mg/day (or equivalent oral corticosteroid) is allowed for chronic use if subject was on a stable dose at least 30 days prior to Visit 1 (screening)~  2. Pirfenidone within 4 weeks prior to Visit 1 (screening)~  3. N-acetylcysteine within 4 weeks prior to Visit 1 (screening)~  4. Live attenuated vaccines within 4 weeks prior to Visit 1 (screening)

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Tralokinumab 400 milligram (mg) (Type: EXPERIMENTAL): Participants will receive Tralokinumab 400 mg intravenous (IV) infusion Q4W for 68 Weeks.
- Tralokinumab 800 mg (Type: EXPERIMENTAL): Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Transcranial Direct Current Stimulation (tDCS) on Patients With Chronic Orofacial Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female between 18 and 75 years old~* Clinic history of previous orofacial and/or dental surgery~* Chronic orofacial pain for more than a year measurable by the VAS more than 3 .~* Pain not responsive to pharmacological treatment (analgesic, anti inflammatory, opiates, antidepressant drugs and physiotherapy modalities)~Exclusion Criteria:~* Contraindication to tDCS: presence of metallic implants that can be stimulated, moved or overheated by electric current, positive anamnesis for epilepsy, implantable systems ( ventriculoperitoneal shunt, pacemaker, intracranial pumps, intracranial metallic systems)~* Major neurological or psychiatric pathologies~* Pregnancy~* Severe hepatorenal and cardiopulmonary diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- sham tDCS (Type: ACTIVE_COMPARATOR): This group will receive sham-tDCS for 5 days. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 30 seconds, with an intensity of 1 milliampere.
- real tDCS (Type: EXPERIMENTAL): This group will receive continuous stimulation lasting 20 minutes daily, for 5 days.~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 20 minutes, with an intensity of 1 milliampere.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues